| Year |
Citation |
Score |
| 2024 |
Lee CH, Yogesh Shah A, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Gironés Sarrió R, Lee Cohn A, Asim Bilen M, Gunnestad Ribe S, Krohn Tennøe Ø, Richards D, Sweis RF, Courtright J, et al. Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146. European Urology. PMID 38777648 DOI: 10.1016/j.eururo.2024.05.003 |
0.364 |
|
| 2024 |
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, ... ... Hsieh JJ, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports. 43: 113063. PMID 38578829 DOI: 10.1016/j.celrep.2023.113063 |
0.384 |
|
| 2023 |
Wu Y, Chen S, Yang X, Sato K, Lal P, Wang Y, Shinkle AT, Wendl MC, Primeau TM, Zhao Y, Gould A, Sun H, Mudd JL, Hoog J, Mashl RJ, ... ... Hsieh J, et al. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Research. 83: 4161-4178. PMID 38098449 DOI: 10.1158/0008-5472.CAN-23-0604 |
0.314 |
|
| 2023 |
Wu Y, Terekhanova NV, Caravan W, Naser Al Deen N, Lal P, Chen S, Mo CK, Cao S, Li Y, Karpova A, Liu R, Zhao Y, Shinkle A, Strunilin I, Weimholt C, ... ... Hsieh JJ, et al. Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. Nature Communications. 14: 2817. PMID 37198186 DOI: 10.1038/s41467-023-38561-y |
0.394 |
|
| 2023 |
Wu Y, Terekhanova NV, Caravan W, Naser Al Deen N, Lal P, Chen S, Mo CK, Cao S, Li Y, Karpova A, Liu R, Zhao Y, Shinkle A, Strunilin I, Weimholt C, ... ... Hsieh JJ, et al. Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. Nature Communications. 14: 1681. PMID 36973268 DOI: 10.1038/s41467-023-37211-7 |
0.399 |
|
| 2022 |
Lee CH, Motzer R, Emamekhoo H, Matrana M, Percent I, Hsieh JJ, Hussain A, Vaishampayan U, Liu S, McCune S, Patel V, Shaheen M, Bendell J, Fan AC, Gartrell BA, et al. Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35576438 DOI: 10.1158/1078-0432.CCR-22-0061 |
0.309 |
|
| 2022 |
Xie Y, Sahin M, Sinha S, Wang Y, Nargund AM, Lyu Y, Han S, Dong Y, Hsieh JJ, Leslie CS, Cheng EH. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nature Cancer. PMID 35115713 DOI: 10.1038/s43018-021-00316-3 |
0.327 |
|
| 2021 |
Niizuma H, Searleman AC, Takeda S, Armstrong SA, Park CY, Cheng EH, Hsieh JJ. Taspase1 orchestrates fetal liver hematopoietic stem cell and vertebrae fates through cleaving TFIIA. Jci Insight. PMID 34156981 DOI: 10.1172/jci.insight.149382 |
0.483 |
|
| 2021 |
Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. The Lancet. Oncology. PMID 34143969 DOI: 10.1016/S1470-2045(21)00241-2 |
0.352 |
|
| 2021 |
Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie R, Bapat U, Ye W, Jain RK, Fishman MN. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. European Urology. PMID 33867192 DOI: 10.1016/j.eururo.2021.03.015 |
0.381 |
|
| 2021 |
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine. 384: 829-841. PMID 33657295 DOI: 10.1056/NEJMoa2026982 |
0.358 |
|
| 2020 |
Huang JJ, Hsieh JJ. The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. Kidney Cancer (Clifton, Va.). 4: 121-129. PMID 33195887 DOI: 10.3233/KCA-200085 |
0.353 |
|
| 2020 |
Hoerner CR, Miao SY, Hsieh JJ, Fan AC. Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities. Cancer Journal (Sudbury, Mass.). 26: 407-418. PMID 32947309 DOI: 10.1097/Ppo.0000000000000472 |
0.406 |
|
| 2020 |
Hsieh JJ. The 2020 Kidney Cancer Treatment Sequence Issue. Clinical Genitourinary Cancer. 18: 241-243. PMID 32768132 DOI: 10.1016/J.Clgc.2020.07.001 |
0.328 |
|
| 2020 |
Hsieh JJ, Cheng EH. Exploiting the circuit breaker cancer evolution model in human clear cell renal cell carcinoma. Cell Stress. 4: 191-198. PMID 32743344 DOI: 10.15698/cst2020.08.227 |
0.346 |
|
| 2020 |
Reimers MA, Figenshau RS, Kim EH, Tucker J, Kasten N, Khan AS, Hanneken JM, Smith ZL, Hsieh JJ. Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer. PMID 32417157 DOI: 10.1016/J.Clgc.2020.04.002 |
0.434 |
|
| 2020 |
Kim K, Hu W, Audenet F, Almassi N, Hanrahan AJ, Murray K, Bagrodia A, Wong N, Clinton TN, Dason S, Mohan V, Jebiwott S, Nagar K, Gao J, Penson A, ... ... Hsieh JJ, et al. Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications. 11: 1975. PMID 32332851 DOI: 10.1038/S41467-020-15885-7 |
0.401 |
|
| 2020 |
Hamieh L, Beck RL, Le VH, Hsieh JJ. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy. Clinical Genitourinary Cancer. PMID 32291161 DOI: 10.1016/J.Clgc.2020.03.003 |
0.442 |
|
| 2020 |
Huang JJ, Hsieh JJ. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age. Seminars in Nephrology. 40: 28-41. PMID 32130964 DOI: 10.1016/J.Semnephrol.2019.12.004 |
0.433 |
|
| 2020 |
Malouf GG, Flippot R, Dong Y, Dinatale RG, Chen YB, Su X, Compérat E, Rouprêt M, Mano R, Blum KA, Yao H, Mouawad R, Spano JP, Khayat D, Karam JA, ... ... Hsieh JJ, et al. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Scientific Reports. 10: 701. PMID 31959902 DOI: 10.1038/S41598-020-57534-5 |
0.485 |
|
| 2020 |
Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, ... ... Hsieh JJ, et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 180: 207. PMID 31923397 DOI: 10.1016/j.cell.2019.12.026 |
0.369 |
|
| 2020 |
Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie S, Bapat U, Jain RK, Fishman MN. A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC). Journal of Clinical Oncology. 38: 685-685. DOI: 10.1200/Jco.2020.38.6_Suppl.685 |
0.381 |
|
| 2020 |
Kim E, Miheecheva N, Ramachandran A, Lyu Y, Galkin I, Svekolkin V, Postovalova E, Bagaev A, Nomie K, Ogloblina A, Frenkel F, Ataullakhanov R, Hsieh JJ, Pachynski RK. Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome. Journal of Clinical Oncology. 38: e17506-e17506. DOI: 10.1200/Jco.2020.38.15_Suppl.E17506 |
0.341 |
|
| 2020 |
Hsieh JJ, Miheecheva N, Ramachandran A, Lyu Y, Galkin I, Svekolkin V, Postovalova E, Bagaev A, Lozinsky Y, Zyrin V, Zaitsev A, Nuzhdina K, Nomie K, Ogloblina A, Frenkel F, et al. Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma. Journal of Clinical Oncology. 38: e17106-e17106. DOI: 10.1200/Jco.2020.38.15_Suppl.E17106 |
0.397 |
|
| 2020 |
Lee C, Shah AY, Hsieh JJ, Rao A, Pinto A, Bilen MA, Cohn AL, Di Simone C, Shaffer DR, Girones Sarrio R, Gunnestad Ribe S, Wu J, Schmidt EV, Perini RF, Kubiak P, et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). Journal of Clinical Oncology. 38: 5008-5008. DOI: 10.1200/Jco.2020.38.15_Suppl.5008 |
0.312 |
|
| 2019 |
Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, ... ... Hsieh JJ, et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 179: 964-983.e31. PMID 31675502 DOI: 10.1016/J.Cell.2019.10.007 |
0.447 |
|
| 2019 |
Casuscelli J, Becerra MF, Seier K, Manley BJ, Benfante N, Redzematovic A, Stief CG, Hsieh JJ, Tickoo SK, Reuter VE, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clinical Genitourinary Cancer. PMID 31326335 DOI: 10.1016/J.Clgc.2019.06.011 |
0.484 |
|
| 2019 |
Xu J, Reznik E, Lee HJ, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra JG, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka ZP, Casuscelli J, ... ... Hsieh JJ, et al. Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. Elife. 8. PMID 30924768 DOI: 10.7554/Elife.38986 |
0.45 |
|
| 2019 |
Poehlman WL, Hsieh JJ, Feltus FA. Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths. Scientific Reports. 9: 2899. PMID 30814637 DOI: 10.1038/S41598-019-39875-Y |
0.451 |
|
| 2019 |
Xu J, Reznik E, Lee H, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra J, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka Z, Casuscelli J, ... ... Hsieh JJ, et al. Author response: Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma Elife. DOI: 10.7554/Elife.38986.025 |
0.449 |
|
| 2019 |
Tanaka K, Han S, Ganesan YT, Hsieh JJ, Cheng EH. Abstract 698: Enhancing apoptosis to improve the therapy ofEGFR-mutant lung cancer Cancer Research. 79: 698-698. DOI: 10.1158/1538-7445.Am2019-698 |
0.33 |
|
| 2019 |
Motzer R, Lee C, Emamekhoo H, Matrana M, Percent I, Hsieh J, Hussain A, Vaishampayan U, Graham R, Liu S, McCune S, Shaheen M, Parmar H, Shen Y, Whiting S, et al. ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC) Annals of Oncology. 30: v889-v890. DOI: 10.1093/Annonc/Mdz394.048 |
0.388 |
|
| 2018 |
Gatto F, Blum KA, Hosseini SS, Ghanaat M, Kashan M, Maccari F, Galeotti F, Hsieh JJ, Volpi N, Hakimi AA, Nielsen J. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma. European Urology Oncology. 1: 364-377. PMID 31158075 DOI: 10.1016/J.Euo.2018.04.015 |
0.43 |
|
| 2018 |
Silk MT, Mikkilineni N, Silk TC, Zabor EC, Ostrovnaya I, Hakimi AA, Hsieh JJ, Ziv E, Rekhtman N, Solomon SB, Durack JC. Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. Analytical Cellular Pathology (Amsterdam). 2018: 2898962. PMID 30652067 DOI: 10.1155/2018/2898962 |
0.333 |
|
| 2018 |
Dong Y, Eskandari R, Ray C, Granlund KL, Dos Santos-Cunha L, Miloushev VZ, Tee SS, Jeong S, Aras O, Chen YB, Cheng EH, Hsieh JJ, Keshari KR. Hyperpolarized MRI visualizes Warburg effects and predicts treatment response to mTOR inhibitors in patient-derived ccRCC xenograft models. Cancer Research. PMID 30459151 DOI: 10.1158/0008-5472.Can-18-2231 |
0.429 |
|
| 2018 |
Voss MH, Reising A, Cheng Y, Patel P, Marker M, Kuo F, Chan TA, Choueiri TK, Hsieh JJ, Hakimi AA, Motzer RJ. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. The Lancet. Oncology. PMID 30416077 DOI: 10.1016/S1470-2045(18)30648-X |
0.501 |
|
| 2018 |
Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH. Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018792549. PMID 30372397 DOI: 10.1200/Jco.2018.79.2549 |
0.509 |
|
| 2018 |
Voss MH, Chen D, Reising A, Marker M, Shi J, Xu J, Ostrovnaya I, Seshan V, Redzematovic A, Chen YB, Patel P, Han X, Hsieh JJ, Hakimi AA, Motzer RJ. PTEN Expression, Not Mutation Status for , or , Correlates With Outcome on Everolimus in Patients With Renal Cell Carcinoma Treated on RECORD-3. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30327302 DOI: 10.1158/1078-0432.Ccr-18-1833 |
0.491 |
|
| 2018 |
Qu L, Wang ZL, Chen Q, Li YM, He HW, Hsieh JJ, Xue S, Wu ZJ, Liu B, Tang H, Xu XF, Xu F, Wang J, Bao Y, Wang AB, et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. European Urology. PMID 30143382 DOI: 10.1016/J.Eururo.2018.07.032 |
0.362 |
|
| 2018 |
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, ... ... Hsieh JJ, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports. 23: 3698. PMID 29925010 DOI: 10.1016/J.Celrep.2018.06.032 |
0.389 |
|
| 2018 |
Gala K, Li Q, Sinha A, Razavi P, Dorso M, Sanchez-Vega F, Chung YR, Hendrickson R, Hsieh J, Berger M, Schultz N, Pastore A, Abdel-Wahab O, Chandarlapaty S. KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. Oncogene. PMID 29755131 DOI: 10.1038/S41388-018-0273-5 |
0.335 |
|
| 2018 |
McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AK, Martini DJ, Wei XX, Braun DA, Van Allen EM, Castellano D, de Velasco G, Wells JC, Heng DYC, ... ... Hsieh J, et al. The Clinical Activity of PD-1/PD-L1 inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunology Research. PMID 29748390 DOI: 10.1158/2326-6066.Cir-17-0475 |
0.301 |
|
| 2018 |
Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, Nicol D, O'Brien T, Larkin J, Horswell S, Stares M, Au L, Jamal-Hanjani M, Challacombe B, Chandra A, ... ... Hsieh JJ, et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell. PMID 29656895 DOI: 10.1016/J.Cell.2018.03.057 |
0.46 |
|
| 2018 |
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, ... ... Hsieh JJ, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports. 23: 313-326.e5. PMID 29617669 DOI: 10.1016/J.Celrep.2018.03.075 |
0.49 |
|
| 2018 |
Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, et al. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R )-4-Fluoroglutamine. Radiology. 162610. PMID 29388903 DOI: 10.1148/Radiol.2017162610 |
0.326 |
|
| 2018 |
Voss MH, Cheng Y, Marker M, Kuo F, Choueiri TK, Hsieh JJ, Reising A, Motzer RJ, Hakimi AA. Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 36: 639-639. DOI: 10.1200/Jco.2018.36.6_Suppl.639 |
0.373 |
|
| 2018 |
Choueiri TK, Apolo AB, Powles T, Escudier B, Aren OR, Shah A, Kessler ER, Hsieh JJ, Zhang J, Simsek B, Scheffold C, Motzer RJ. A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). Journal of Clinical Oncology. 36: TPS4598-TPS4598. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps4598 |
0.41 |
|
| 2018 |
Voss MH, Buros Novik J, Hellmann MD, Ball M, Hakimi AA, Miao D, Margolis C, Horak C, Wind-Rotolo M, De Velasco G, Tannir NM, Tamboli P, Appleman LJ, Rathmell K, Hsieh JJ, et al. Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC). Journal of Clinical Oncology. 36: 4518-4518. DOI: 10.1200/Jco.2018.36.15_Suppl.4518 |
0.393 |
|
| 2018 |
Blum KA, Gatto F, Ghannat M, Sanchez A, Maccari F, Galeotti F, Hsieh J, Volpi N, Hakimi AA, Nielsen J. MP72-19 PLASMA GLYCOSAMINOGLYCAN SCORES IN RENAL CELL CARCINOMA Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2303 |
0.42 |
|
| 2017 |
Casuscelli J, Vano YA, Fridman WH, Hsieh JJ. Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice. Kidney Cancer. 1: 3-13. PMID 30334000 DOI: 10.3233/KCA-170008 |
0.379 |
|
| 2017 |
Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. The Journal of Pathology. PMID 29266437 DOI: 10.1002/Path.5022 |
0.47 |
|
| 2017 |
Wang GX, Tu HC, Dong Y, Skanderup AJ, Wang Y, Takeda S, Ganesan YT, Han S, Liu H, Hsieh JJ, Cheng EH. ΔNp63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. Cell Reports. 21: 2926-2939. PMID 29212036 DOI: 10.1016/J.Celrep.2017.11.030 |
0.561 |
|
| 2017 |
Manley BJ, Reznik E, Ghanaat M, Kashan M, Becerra MF, Casuscelli J, Tennenbaum D, Redzematovic A, Carlo MI, Sato Y, Arcila M, Voss MH, Feldman DR, Motzer RJ, Russo P, ... ... Hsieh JJ, et al. Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. Urologic Oncology. PMID 29132830 DOI: 10.1016/J.Urolonc.2017.10.012 |
0.476 |
|
| 2017 |
Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, DiNatale RG, Blum KA, Durack JC, Solomon SB, Arcila ME, Bourque C, ... ... Hsieh JJ, et al. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus. PMID 29066084 DOI: 10.1016/J.Euf.2017.09.016 |
0.487 |
|
| 2017 |
Casuscelli J, Hsieh JJ. Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma? European Urology. PMID 29032154 DOI: 10.1016/J.Eururo.2017.09.026 |
0.434 |
|
| 2017 |
Mar BG, Chu SH, Kahn JD, Krivstov AV, Koche R, Castellano CA, Kotlier JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. PMID 29018079 DOI: 10.1182/Blood-2017-03-775569 |
0.305 |
|
| 2017 |
Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, ... ... Hsieh JJ, et al. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. European Urology Focus. PMID 28951115 DOI: 10.1016/J.Euf.2017.09.008 |
0.428 |
|
| 2017 |
Nargund AM, Osmanbeyoglu HU, Cheng EH, Hsieh JJ. SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer. Molecular & Cellular Oncology. 4: e1342747. PMID 28868352 DOI: 10.1080/23723556.2017.1342747 |
0.405 |
|
| 2017 |
Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ. Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nature Communications. 8: 199. PMID 28775315 DOI: 10.1038/S41467-017-00289-X |
0.382 |
|
| 2017 |
Rosenzweig B, Rubinstein ND, Reznik E, Shingarev R, Juluru K, Akin O, Hsieh JJ, Jaimes EA, Russo P, Susztak K, Coleman JA, Hakimi AA. Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients. Plos One. 12: e0180350. PMID 28727768 DOI: 10.1371/Journal.Pone.0180350 |
0.451 |
|
| 2017 |
Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, et al. Recommendations for the Management of Rare Kidney Cancers. European Urology. PMID 28720391 DOI: 10.1016/J.Eururo.2017.06.040 |
0.465 |
|
| 2017 |
Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, Hellmann MD, Kris MG, Hsieh JJ, Cheng EH. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nature Communications. 8: 16078. PMID 28714472 DOI: 10.1038/Ncomms16078 |
0.354 |
|
| 2017 |
Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, ... ... Hsieh JJ, et al. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. Jci Insight. 2. PMID 28614790 DOI: 10.1172/Jci.Insight.92688 |
0.429 |
|
| 2017 |
Carlo MI, Chaim J, Patil S, Kemel Y, Schram AM, Woo K, Coskey D, Nanjangud GJ, Voss MH, Feldman DR, Hsieh JJ, Hakimi AA, Chen YB, Motzer RJ, Lee CH. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. Clinical Genitourinary Cancer. PMID 28558987 DOI: 10.1016/J.Clgc.2017.04.012 |
0.444 |
|
| 2017 |
Sinha R, Winer AG, Chevinsky M, Jakubowski C, Chen YB, Dong Y, Tickoo SK, Reuter VE, Russo P, Coleman JA, Sander C, Hsieh JJ, Hakimi AA. Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nature Communications. 8: 15165. PMID 28489074 DOI: 10.1038/Ncomms15165 |
0.484 |
|
| 2017 |
Tennenbaum DM, Manley BJ, Zabor E, Becerra MF, Carlo MI, Casuscelli J, Redzematovic A, Khan N, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Benfante NE, Coleman JA, Russo P, ... Hsieh JJ, et al. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urologic Oncology. PMID 28408295 DOI: 10.1016/J.Urolonc.2017.03.015 |
0.497 |
|
| 2017 |
Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, Ray CE, Dong Z, Berge M, Hakimi AA, Monette S, ... ... Hsieh JJ, et al. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell Reports. 18: 2893-2906. PMID 28329682 DOI: 10.1016/J.Celrep.2017.02.074 |
0.657 |
|
| 2017 |
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nature Reviews. Disease Primers. 3: 17009. PMID 28276433 DOI: 10.1038/nrdp.2017.9 |
0.414 |
|
| 2017 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Hsieh JJ, et al. Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 18: 46. PMID 28249590 DOI: 10.1186/S13059-017-1180-8 |
0.451 |
|
| 2017 |
de Velasco G, Culhane AC, Fay AP, Ari Hakimi A, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. The Oncologist. PMID 28220024 DOI: 10.1634/Theoncologist.2016-0078 |
0.436 |
|
| 2017 |
Hsieh JJ, Marker M, Chen D. Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.10.007. European Urology. PMID 28111113 DOI: 10.1016/J.Eururo.2017.01.013 |
0.385 |
|
| 2017 |
Ghanaat M, Liu M, Manley B, Kashan M, Becerra M, Redzematovic A, Coleman J, Russo P, Hsieh J, Li M, Hakimi AA. Immune cell phenotyping of clear cell renal cell carcinoma. Journal of Clinical Oncology. 35: 511-511. DOI: 10.1200/Jco.2017.35.6_Suppl.511 |
0.376 |
|
| 2017 |
Voss MH, Chen D, Marker M, Xu J, Patel P, Han X, Hsieh J, Motzer RJ. Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving first-line everolimus: Correlation between outcome and mutations status in MTOR, TSC1, and TSC2. Journal of Clinical Oncology. 35: 484-484. DOI: 10.1200/Jco.2017.35.6_Suppl.484 |
0.369 |
|
| 2017 |
Carlo MI, Khan N, Chen Y, Hsieh J, Hakimi AA, Lee C, Feldman DR, Motzer RJ, Voss MH. The genomic landscape of metastatic non-clear cell renal cell carcinoma. Journal of Clinical Oncology. 35: 474-474. DOI: 10.1200/Jco.2017.35.6_Suppl.474 |
0.481 |
|
| 2017 |
Rosenzweig B, Rubinstein ND, Reznik E, Zareba P, Shingarev R, Juluru K, Akin O, Hsieh J, Jaimes EA, Russo P, Susztak K, Coleman J, Hakimi AA. Effect of benign and tumor parenchyma metabolomic profiles on compensatory renal growth in renal cell carcinoma surgical patients. Journal of Clinical Oncology. 35: 446-446. DOI: 10.1200/Jco.2017.35.6_Suppl.446 |
0.405 |
|
| 2017 |
Kim K, Murray KS, Bagrodia A, Audenet F, Jebiwott S, Gordon B, Somma A, LaRosa S, Dong Y, Alvim R, Hakimi AA, Hsieh J, Al-Ahmadie H, Rosenberg JE, Solit DB, et al. Patient derived xenografts of upper tract urothelial carcinoma: A potential tool for personalized medicine. Journal of Clinical Oncology. 35: 344-344. DOI: 10.1200/Jco.2017.35.6_Suppl.344 |
0.424 |
|
| 2017 |
Voss MH, Kuo F, Chen D, Marker M, Patel P, Redzematovic A, Riaz N, Chan TA, Choueiri TK, Hsieh J, Motzer RJ, Hakimi AA. Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy. Journal of Clinical Oncology. 35: 4523-4523. DOI: 10.1200/Jco.2017.35.15_Suppl.4523 |
0.373 |
|
| 2017 |
Rosenzweig B, Rubinstein ND, Reznik E, Zareba P, Shingarev R, Juluru K, Akin O, Hsieh JJ, Jaimes E, Russo P, Susztak K, Coleman JA, Hakimi AA. MP73-17 BENIGN AND TUMOR PARENCHYMA METABOLOMIC PROFILES AFFECT COMPENSATORY RENAL GROWTH IN RENAL CELL CARCINOMA SURGICAL PATIENTS Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3362 |
0.46 |
|
| 2017 |
Kim K, Murray K, Bagrodia A, Audenet F, Jebiwott S, Gordon B, Somma A, LaRosa S, Dong Y, Alvim R, Hakimi AA, Hsieh J, Al-Ahmadie H, Rosenberg J, Solit D, et al. MP88-17 PATIENT DERIVED XENOGRAFTS OF UPPER TRACT UROTHELIAL CARCINOMA: A POTENTIAL TOOL FOR PERSONALIZED MEDICINE Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2742 |
0.317 |
|
| 2017 |
Ghanaat M, Kashan M, Becerra M, Manley B, Casuscelli J, Mendonca S, Redzematovic A, Arcila M, Russo P, Coleman J, Hsieh J, Chen Y, Hakimi AA. MP39-04 MOLECULAR AND CLINICAL CHARACTERIZATION OF RENAL CELL CARCINOMA WITH UNCLASSIFIED HISTOLOGY:
NF2
LOSS PREDICTS WORST OUTCOMES Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1178 |
0.418 |
|
| 2017 |
Becerra M, Sanchez-Vega F, Reznik E, Manley B, Kashan M, Ghanaat M, Casuscelli J, Redzematovic A, Mendonca S, Arcila M, Coleman J, Russo P, Hsieh J, Hakimi AA. MP39-03 IMPACT OF SOMATIC MUTATIONS ON PATTERNS OF METASTASIS IN CLEAR CELL RENAL CELL CARCINOMA Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1177 |
0.481 |
|
| 2017 |
Becerra M, Reznik E, Tennenbaum D, Kashan M, Ghanaat M, Casuscelli J, Manley B, Redzematovic A, Mendonca S, Arcila M, Coleman J, Russo P, Hsieh J, Hakimi AA. MP39-02 COMPARATIVE GENOMIC PROFILING OF MATCHED PRIMARY AND METASTATIC TUMORS IN RENAL CELL CARCINOMA Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1176 |
0.48 |
|
| 2017 |
Manley B, Reznik E, Becerra M, Casuscelli J, Tennenbaum D, Ghanaat M, Kashan M, Redzematovic A, Sato Y, Arcila M, Voss M, Feldman D, Russo P, Coleman J, Hsieh J, et al. MP39-01 CHARACTERIZING RECURRENT AND LETHAL SMALL RENAL MASSES IN CLEAR CELL RENAL CELL CARCINOMA USING SOMATIC MUTATIONS Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1175 |
0.478 |
|
| 2016 |
Manley BJ, Hsieh JJ. Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components. Translational Cancer Research. 5: S160-S165. PMID 29167760 DOI: 10.21037/Tcr.2016.07.30 |
0.474 |
|
| 2016 |
Dong Y, Manley BJ, Becerra MF, Redzematovic A, Casuscelli J, Tennenbaum DM, Reznik E, Han S, Benfante N, Chen YB, Arcila ME, Aras O, Voss MH, Feldman DR, Motzer RJ, ... ... Hsieh JJ, et al. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European Urology Focus. PMID 28753786 DOI: 10.1016/J.Euf.2016.08.005 |
0.464 |
|
| 2016 |
Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH, ... ... Hsieh JJ, et al. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. European Urology Focus. PMID 28753773 DOI: 10.1016/J.Euf.2016.06.015 |
0.483 |
|
| 2016 |
Hsieh JJ, Cheng EH. The panoramic view of clear cell renal cell carcinoma metabolism: values of integrated global cancer metabolomics. Translational Andrology and Urology. 5: 984-986. PMID 28078239 DOI: 10.21037/Tau.2016.11.03 |
0.4 |
|
| 2016 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Hsieh JJ, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 17: 231. PMID 27855702 DOI: 10.1186/S13059-016-1092-Z |
0.405 |
|
| 2016 |
Hsieh JJ, Cheng EH. A braided cancer river connects tumor heterogeneity and precision medicine. Clinical and Translational Medicine. 5: 42. PMID 27766604 DOI: 10.1186/S40169-016-0123-4 |
0.369 |
|
| 2016 |
Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, Selcuklu SD, Weinhold N, Bouvier N, Huberman KH, Bhanot U, Chevinsky MS, Patel P, Pinciroli P, Won HH, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European Urology. PMID 27751729 DOI: 10.1016/J.Eururo.2016.10.007 |
0.457 |
|
| 2016 |
Chen YB, Xu J, Skanderup AJ, Dong Y, Brannon AR, Wang L, Won HH, Wang PI, Nanjangud GJ, Jungbluth AA, Li W, Ojeda V, Hakimi AA, Voss MH, Schultz N, ... ... Hsieh JJ, et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications. 7: 13131. PMID 27713405 DOI: 10.1038/Ncomms13131 |
0.51 |
|
| 2016 |
Hsieh JJ, Manley B, Khan N, Gao J, Carlo MI, Cheng EH. Overcome Tumor Heterogeneity-Imposed Therapeutic Barriers through Convergent Genomic Biomarker Discovery: A Braided Cancer River Model of Kidney Cancer. Seminars in Cell & Developmental Biology. PMID 27615548 DOI: 10.1016/J.Semcdb.2016.09.002 |
0.423 |
|
| 2016 |
Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, ... Hsieh JJ, et al. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27601542 DOI: 10.1200/Jco.2016.67.9084 |
0.498 |
|
| 2016 |
De Velasco G, Miao DD, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen E, Choueiri TK. Tumor mutational load and immune parameters across metastatic Renal Cell Carcinoma (mRCC) risk groups. Cancer Immunology Research. PMID 27538576 DOI: 10.1158/2326-6066.Cir-16-0110 |
0.407 |
|
| 2016 |
Xu J, Pham CG, Albanese SK, Dong Y, Oyama T, Lee CH, Rodrik-Outmezguine V, Yao Z, Han S, Chen D, Parton DL, Chodera JD, Rosen N, Cheng EH, Hsieh JJ. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. The Journal of Clinical Investigation. PMID 27482884 DOI: 10.1172/Jci86120 |
0.41 |
|
| 2016 |
Carlo MI, Molina AM, Lakhman Y, Patil S, Woo K, DeLuca J, Lee CH, Hsieh JJ, Feldman DR, Motzer RJ, H Voss M. A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. The Oncologist. PMID 27286790 DOI: 10.1634/Theoncologist.2016-0145 |
0.467 |
|
| 2016 |
Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, ... ... Hsieh JJ, et al. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Reports. PMID 26947078 DOI: 10.1016/J.Celrep.2016.02.024 |
0.483 |
|
| 2016 |
Voss MH, Hsieh JJ. Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26920890 DOI: 10.1158/1078-0432.Ccr-16-0035 |
0.37 |
|
| 2016 |
Voss MH, Chen D, Marker M, Hakimi AA, Lee CH, Hsieh JJ, Knox JJ, Voi M, Motzer RJ. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. British Journal of Cancer. PMID 26908330 DOI: 10.1038/Bjc.2016.21 |
0.442 |
|
| 2016 |
Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, ... ... Hsieh JJ, et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 29: 104-116. PMID 26766592 DOI: 10.1016/J.Ccell.2015.12.004 |
0.391 |
|
| 2016 |
Winer AG, Senbabaoglu Y, Gejman R, Ostrovnaya I, Kaffenberger SD, Voss MH, Coleman JA, Russo P, Hsieh J, Sander C, Hakimi AA. The immune landscape of renal cell carcinoma and its association with intratumoral clonality. Journal of Clinical Oncology. 34: 605-605. DOI: 10.1200/Jco.2016.34.2_Suppl.605 |
0.406 |
|
| 2016 |
Hsieh J, Chen D, Wang P, Chen Y, Marker M, Patel P, Chevinsky M, Bhanot U, Pinciroli P, Berger MF, Cheng E, Lee W, Knox JJ, Voss MH, Voi M, et al. Differential overall survival (OS) results in RECORD-3 study based on three distinct mRCC molecular subgroups classified by BAP1 and/or PBRM1 mutations. Journal of Clinical Oncology. 34: 561-561. DOI: 10.1200/Jco.2016.34.2_Suppl.561 |
0.369 |
|
| 2016 |
Manley B, Tennenbaum D, Casuscelli J, Hsieh J. Assessing the frequency of somatic mutations in high-risk clear cell renal cell carcinoma to provide new perspectives. Journal of Clinical Oncology. 34: 548-548. DOI: 10.1200/Jco.2016.34.2_Suppl.548 |
0.449 |
|
| 2016 |
Manley B, Casuscelli J, Tennenbaum D, Hakimi AA, Hsieh J. Analysis of mutational status in recurrently mutated genes in clear cell renal cell carcinoma and overall survival in patients with metastatic disease at time of nephrectomy. Journal of Clinical Oncology. 34: 520-520. DOI: 10.1200/Jco.2016.34.2_Suppl.520 |
0.464 |
|
| 2016 |
Dong Y, Manley B, Hakimi AA, Coleman JA, Russo P, Hsieh J. Comparing surgical tissue versus biopsy tissue in the development of a clear cell renal cell carcinoma xenograft model. Journal of Clinical Oncology. 34: 519-519. DOI: 10.1200/Jco.2016.34.2_Suppl.519 |
0.36 |
|
| 2016 |
Casuscelli J, Wang P, Redzematovic A, Lee W, Seshan VE, Shen R, Donin N, Chen Y, Cheville JC, Pantuck AJ, Thompson RH, Coleman JA, Russo P, Reuter VE, Tickoo S, ... ... Hsieh J, et al. Understanding the genomic underpinnings of metastatic chromophobe renal cell carcinoma. Journal of Clinical Oncology. 34: 513-513. DOI: 10.1200/Jco.2016.34.2_Suppl.513 |
0.438 |
|
| 2016 |
Casuscelli J, Winer AG, Reznik E, Xu J, Manley B, Chouhan J, Reuter VE, Tickoo S, Russo P, Coleman JA, Hsieh J, Hakimi AA. Single-institutional analysis of patients with clear-cell papillary renal cell carcinoma. Journal of Clinical Oncology. 34: 512-512. DOI: 10.1200/Jco.2016.34.2_Suppl.512 |
0.485 |
|
| 2016 |
Voss MH, Chen D, Marker M, Knox J, Hsieh J, Voi M, Motzer RJ. Baseline lactate dehydrogenase (LDH) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with everolimus (EVE) versus sunitinib (SUN): Predictive biomarker analysis from the RECORD-3 trial. Journal of Clinical Oncology. 34: e16118-e16118. DOI: 10.1200/Jco.2016.34.15_Suppl.E16118 |
0.383 |
|
| 2016 |
Lee C, Wei E, Lee W, Chen Y, Mano R, Hakimi AA, Dong Y, Redzematovic A, Cross JR, Tickoo S, Srinivasan R, Oschwald D, Reuter VE, Dunphy M, Cheng E, ... ... Hsieh J, et al. Genomic and metabolic characterization of succinate dehydrogenase B deficient renal cell carcinoma. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16102 |
0.453 |
|
| 2016 |
Carlo MI, Chen Y, Chaim J, Coskey DT, Woo K, Hsieh J, Voss MH, Feldman DR, Motzer RJ, Lee C. Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes. Journal of Clinical Oncology. 34: 4556-4556. DOI: 10.1200/Jco.2016.34.15_Suppl.4556 |
0.482 |
|
| 2016 |
Inoue-Yamauchi A, Jeng P, Kim K, Chen H, Han S, Ganesan YT, Dong Y, Jebiwott S, Hsieh JJ, Cheng EH. Abstract 3555: Targeting the BCL-2 family in small cell lung caner Cancer Research. 76: 3555-3555. DOI: 10.1158/1538-7445.Am2016-3555 |
0.364 |
|
| 2016 |
Casuscelli J, Manley B, Redzematovic A, Becerra M, Tennenbaum D, Arcila M, Voss M, Feldman D, Motzer R, Coleman J, Russo P, Hsieh J, Hakimi A. 229 Significance of TERT variants in renal cell carcinoma European Urology Supplements. 15: e229. DOI: 10.1016/S1569-9056(16)60231-2 |
0.469 |
|
| 2016 |
Rosenzweig B, Reznik E, Shingarev R, Zabor EC, Stirdivant S, Sander C, Hsieh JJ, Jaimes EA, Russo P, Hakimi AA, Coleman JA. MP85-20 METABOLOMICS AND POST-NEPHRECTOMY RENAL FUNCTION PREDICTION Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2286 |
0.357 |
|
| 2016 |
Casuscelli J, Winer AG, Reznik E, Xu J, Manley BJ, Chouhan J, Reuter VE, Tickoo SK, Russo P, Coleman JA, Hsieh JJ, Hakimi AA. MP73-17 SINGLE-INSTITUTIONAL ANALYSIS OF PATIENTS WITH CLEAR-CELL PAPILLARY RENAL CELL CARCINOMA Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1672 |
0.474 |
|
| 2016 |
Casuscelli J, Manley BJ, Mano R, Redzematovic A, Becerra MF, Tennenbaum DM, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Coleman JA, Russo P, Hsieh JJ, Hakimi AA. MP71-14 ANALYSIS OF THE MUTATIONAL LANDSCAPE OF SARCOMATOID CLEAR CELL RENAL CELL CARCINOMA COMPARED TO CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1460 |
0.493 |
|
| 2016 |
Becerra MF, Manley BJ, Casuscelli J, Redzematovic A, Tennenbaum DM, Motzer RJ, Feldman DR, Voss MH, Arcila M, Russo P, Coleman JA, Hsieh JJ, Hakimi AA. MP71-11 GENOMIC LANSCAPE OF CLEAR CELL RENAL CELL CARCINOMA METASTASIS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1457 |
0.483 |
|
| 2016 |
Manley BJ, Casuscelli J, Tennenbaum DM, Becerra MF, Redzematovic A, Arcila ME, Voss MH, Feldman DR, Coleman JA, Russo P, Motzer RJ, Hsieh JJ, Hakimi AA. MP71-10 CLINICAL FEATURES OF RECURRENT SOMATIC MUTATIONS IN CLEAR CELL RENAL CELL CARCINOMA: A LARGE COHORT Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1456 |
0.475 |
|
| 2016 |
Casuscelli J, Manley BJ, Redzematovic A, Becerra MF, Tennenbaum DM, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Russo P, Coleman JA, Hsieh JJ, Hakimi AA. MP71-06 THE IMPACT OF
TERT
PROMOTER REGION MUTATIONS IN RENAL CELL CARCINOMA Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1452 |
0.457 |
|
| 2016 |
Dong Y, Manley BJ, Hakimi AA, Becerra MF, Russo P, Coleman JA, Hsieh JJ. MP71-03 DEVELOPMENT OF A CLEAR CELL RENAL CELL CARCINOMA XENOGRAFT MODEL: A CASE FOR THE USE OF BIOPSY TISSUE OVER SURGICAL TISSUE Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1449 |
0.407 |
|
| 2016 |
Albanese S, Xu J, Hsieh J, Chodera JD. Simulating mTOR Hyperactivating Mutations to Understand Functionally Significant Structural Rearrangements Biophysical Journal. 110: 207a. DOI: 10.1016/J.Bpj.2015.11.1152 |
0.372 |
|
| 2015 |
Niizuma H, Cheng EH, Hsieh JJ. Taspase 1: A protease with many biological surprises. Molecular & Cellular Oncology. 2: e999513. PMID 27308523 DOI: 10.1080/23723556.2014.999513 |
0.326 |
|
| 2015 |
Joshi S, Tolkunov D, Aviv H, Hakimi AA, Yao M, Hsieh JJ, Ganesan S, Chan CS, White E. The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Reports. 13: 1895-908. PMID 26655904 DOI: 10.1016/J.Celrep.2015.10.059 |
0.409 |
|
| 2015 |
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, ... ... Hsieh J, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. The New England Journal of Medicine. PMID 26536169 DOI: 10.1056/Nejmoa1505917 |
0.501 |
|
| 2015 |
Wei EY, Hsieh JJ. A river model to map convergent cancer evolution and guide therapy in RCC. Nature Reviews. Urology. 12: 706-12. PMID 26526752 DOI: 10.1038/Nrurol.2015.260 |
0.408 |
|
| 2015 |
Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R, Sankin AI, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, ... ... Hsieh JJ, et al. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer. PMID 26505625 DOI: 10.1002/cncr.29765 |
0.423 |
|
| 2015 |
Wei EY, Chen YB, Hsieh JJ. Genomic characterisation of two cancers of unknown primary cases supports a kidney cancer origin. Bmj Case Reports. 2015. PMID 26494726 DOI: 10.1136/Bcr-2015-212685 |
0.411 |
|
| 2015 |
Lee CH, Hötker AM, Voss MH, Feldman DR, Woo KM, Patil S, Coskey DT, Akin O, Hsieh JJ, Motzer RJ. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clinical Genitourinary Cancer. PMID 26404107 DOI: 10.1016/J.Clgc.2015.07.010 |
0.392 |
|
| 2015 |
Chen HC, Kanai M, Inoue-Yamauchi A, Tu HC, Huang Y, Ren D, Kim H, Takeda S, Reyna DE, Chan PM, Ganesan YT, Liao CP, Gavathiotis E, Hsieh JJ, Cheng EH. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nature Cell Biology. PMID 26344567 DOI: 10.1038/Ncb3236 |
0.52 |
|
| 2015 |
Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Research. 75: 2541-52. PMID 25952651 DOI: 10.1158/0008-5472.Can-14-1703 |
0.417 |
|
| 2015 |
Sankin A, Hakimi AA, Hsieh JJ, Molina AM. Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Frontiers in Oncology. 5: 67. PMID 25905038 DOI: 10.3389/Fonc.2015.00067 |
0.477 |
|
| 2015 |
Hakimi AA, Tickoo SK, Jacobsen A, Sarungbam J, Sfakianos JP, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB, Sankin AI, Mano R, Coleman JA, Russo P, ... ... Hsieh JJ, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28: 845-53. PMID 25676555 DOI: 10.1038/Modpathol.2015.6 |
0.512 |
|
| 2015 |
Takeda S, Sasagawa S, Oyama T, Searleman AC, Westergard TD, Cheng EH, Hsieh JJ. Taspase1-dependent TFIIA cleavage coordinates head morphogenesis by limiting Cdkn2a locus transcription. The Journal of Clinical Investigation. 125: 1203-14. PMID 25664857 DOI: 10.1172/Jci77075 |
0.544 |
|
| 2015 |
Lee C, Hoetker AM, Voss MH, Feldman DR, Woo K, Patil S, Coskey DT, Akin O, Hsieh J, Motzer RJ. Bevacizumab monotherapy as salvage therapy for patients with advanced clear cell renal cell carcinoma pretreated with targeted drugs. Journal of Clinical Oncology. 33: 468-468. DOI: 10.1200/Jco.2015.33.7_Suppl.468 |
0.359 |
|
| 2015 |
Voss MH, Chen Y, Chaim J, Coskey DT, Woo K, Patil S, Molina AM, Hsieh J, Motzer RJ, Feldman DR. A phase II trial of everolimus and bevacizumab in advanced non-clear cell renal cell cancer. Journal of Clinical Oncology. 33: 411-411. DOI: 10.1200/Jco.2015.33.7_Suppl.411 |
0.414 |
|
| 2015 |
Kaffenberger SD, Ciriello G, Winer AG, Voss MH, Maranchie JK, Tamboli P, Rathmell K, Choueiri TK, Motzer RJ, Coleman JA, Russo P, Hsieh J, Hakimi AA. Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation. Journal of Clinical Oncology. 33: 406-406. DOI: 10.1200/Jco.2015.33.7_Suppl.406 |
0.375 |
|
| 2015 |
de Velasco G, Fay AP, Culhane A, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Rathmell K, Albiges LK, Hsieh J, Heng DYC, Signoretti S, Choueiri TK. Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data. Journal of Clinical Oncology. 33: 4560-4560. DOI: 10.1200/Jco.2015.33.15_Suppl.4560 |
0.388 |
|
| 2015 |
Voss MH, Chen Y, Chaim J, Coskey DT, Woo K, Redzematovic A, Wang P, Lee W, Patil S, Molina AM, Hsieh J, Motzer R, Feldman DR. A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features. Journal of Clinical Oncology. 33: 4522-4522. DOI: 10.1200/Jco.2015.33.15_Suppl.4522 |
0.419 |
|
| 2015 |
Hsieh J, Chen D, Wang P, Chen Y, Redzematovic A, Marker M, Patel P, Chevinsky M, Bhanot U, Pinciroli P, Bouvier N, Huberman KH, Berger MF, Socci ND, Cheng E, et al. Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3. Journal of Clinical Oncology. 33: 4509-4509. DOI: 10.1200/Jco.2015.33.15_Suppl.4509 |
0.477 |
|
| 2015 |
Dunphy M, Harding JJ, Lewis JS, Mellinghoff IK, Omuro AMP, Hsieh J, Zhang H, Zanzonico P, Venneti S, Carlin S, Younes A, Gerecitano JF, Lyashchenko SK, Harris L, Lashley A, et al. Phenotypic correlation of tumor uptake of exogenous glutamine radiotracer versus tumor mutational status. Journal of Clinical Oncology. 33: 11014-11014. DOI: 10.1200/Jco.2015.33.15_Suppl.11014 |
0.332 |
|
| 2015 |
Glen H, Hsieh J, Michaelson M, Kim H, Sachdev P, Kadowaki T, Funahashi Y, Larkin J, Motzer R. 432 Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-targeted therapy European Journal of Cancer. 51: S89. DOI: 10.1016/S0959-8049(16)30266-0 |
0.316 |
|
| 2015 |
Wei EY, Chen Y, Hsieh JJ. Mp69-18 Genetic Characterization Of Metastatic Renal Cell Carcinoma Lacking Primary Renal Mass The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2522 |
0.446 |
|
| 2015 |
Sankin A, Winer A, Hakimi AA, Wei E, Chevinsky M, Silk T, Jakubowski C, Jacques F, Durack J, Coleman J, Berger M, Russo P, Hsieh J. Pd33-02 Overcoming The Obstacle Of Intratumor Genetic Heterogeneity In Renal Cell Carcinoma Through Ultra Deep Sequencing Of Pooled Regional Tumor Dna The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2100 |
0.405 |
|
| 2015 |
Kaffenberger S, Ostrovnaya I, Winer A, Reuter V, Coleman J, Russo P, Hsieh J, Hakimi A. MP44-07 A CRITICAL ANALYSIS AND VALIDATION OF THE RENAL CELL CARCINOMA BIOMARKER LITERATURE USING THE CANCER GENOME ATLAS (TCGA) Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1549 |
0.479 |
|
| 2015 |
Casuscelli J, Lee W, Wang P, Russo P, Coleman JA, Pantuck A, Thompson RH, Reuter VE, Hakimi AA, Hsieh JJ. MP47-14 MUTATION ANALYSIS OF AGGRESSIVE CHROMOPHOBE RENAL CELL CANCER PATIENTS Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1534 |
0.465 |
|
| 2015 |
Winer A, Senbabaoglu Y, Kaffenberger S, Coleman J, Russo P, Sander C, Hsieh J, Hakimi A. MP47-13 MUTATIONAL AND PROGNOSTIC ASSOCIATIONS OF IMMUNE CELL SIGNATURES IN CLEAR CELL RENAL CELL CARCINOMA Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1533 |
0.474 |
|
| 2015 |
Mano R, Lee W, Sankin A, Chevinsky M, Wang P, Djesevic A, Motzer R, Cheng E, Russo P, Oschwald D, Bhanot U, Tickoo S, Hakimi AA, Hsieh J. MP47-09 MOLECULAR CHARACTERIZATION OF SARCOMATOID CLEAR CELL RENAL CELL CARCINOMA Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1529 |
0.444 |
|
| 2015 |
Winer AG, Hoetker A, Vacchio MJ, Zabor EC, Ostravnaya I, Russo P, Hsieh JJ, Akin O, Hakimi AA. MP35-03 RADIOGENOMICS OF CLEAR CELL RENAL CELL CARCINOMA: ASSOCIATIONS BETWEEN IMAGING, MOLECULAR ALTERATIONS AND PATHOLOGIC FEATURES Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1104 |
0.446 |
|
| 2015 |
Kaffenberger S, Ciriello G, Winer A, Voss M, Maranchie J, Tamboli P, Rathmell K, Choueiri T, Motzer R, Coleman J, Russo P, Sander C, Hsieh J, Hakimi A. MP35-01 PROTEOMIC STRATIFICATION OF CLEAR CELL RENAL CELL CARCINOMA UTILIZING THE CANCER GENOME ATLAS (TCGA) WITH EXTERNAL VALIDATION Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1102 |
0.496 |
|
| 2015 |
Lee CH, Pham CG, Hsieh JJ. PBRM1: A critical subunit of the SWI/SNF chromatin remodeling complex Renal Cell Carcinoma: Molecular Targets and Clinical Applications. 111-151. DOI: 10.1007/978-1-4939-1622-1_5 |
0.309 |
|
| 2014 |
Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, et al. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. Plos One. 9: e116101. PMID 25542006 DOI: 10.1371/Journal.Pone.0116101 |
0.462 |
|
| 2014 |
Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. Bmc Medical Research Methodology. 14: 138. PMID 25532962 DOI: 10.1186/1471-2288-14-138 |
0.406 |
|
| 2014 |
Dong Y, Van Tine BA, Oyama T, Wang PI, Cheng EH, Hsieh JJ. Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis. Cell Research. 24: 1354-66. PMID 25267403 DOI: 10.1038/Cr.2014.129 |
0.318 |
|
| 2014 |
Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I, Crockford A, Favero F, Quidville V, André F, Navas C, ... ... Hsieh JJ, et al. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biology. 15: 433. PMID 25159823 DOI: 10.1186/S13059-014-0433-Z |
0.443 |
|
| 2014 |
Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, ... ... Hsieh JJ, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 26: 319-30. PMID 25155756 DOI: 10.1016/J.Ccr.2014.07.014 |
0.474 |
|
| 2014 |
Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Medicine. 3: 1485-92. PMID 25124064 DOI: 10.1002/Cam4.293 |
0.396 |
|
| 2014 |
Liu H, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell. 25: 530-42. PMID 24735925 DOI: 10.1016/J.Ccr.2014.03.008 |
0.346 |
|
| 2014 |
Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, ... ... Hsieh JJ, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1955-64. PMID 24622468 DOI: 10.1158/1078-0432.CCR-13-2345 |
0.619 |
|
| 2014 |
Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. European Urology. 66: 77-84. PMID 24613583 DOI: 10.1016/J.Eururo.2014.02.035 |
0.441 |
|
| 2014 |
Hakimi AA, Mano R, Ciriello G, Gonen M, Mikkilineni N, Sfakianos JP, Kim PH, Motzer RJ, Russo P, Reuter VE, Hsieh JJ, Ostrovnaya I. Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma. The Journal of Urology. 192: 24-9. PMID 24518768 DOI: 10.1016/J.Juro.2014.01.088 |
0.521 |
|
| 2014 |
Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 663-8. PMID 24458473 DOI: 10.1093/Annonc/Mdt578 |
0.424 |
|
| 2014 |
Funakoshi T, Lee CH, Hsieh JJ. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treatment Reviews. 40: 533-47. PMID 24398141 DOI: 10.1016/J.Ctrv.2013.11.008 |
0.396 |
|
| 2014 |
Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, Hricak H, Motzer R, Hsieh JJ, Akin O. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology. 270: 464-71. PMID 24029645 DOI: 10.1148/Radiol.13130663 |
0.443 |
|
| 2014 |
Lee C, Voss MH, Mano R, Motzer RJ, Hsieh J. Src pathway activation in RCC and the correlation with grade and survival and the development of a rational new target in RCC. Journal of Clinical Oncology. 32: 453-453. DOI: 10.1200/Jco.2014.32.4_Suppl.453 |
0.399 |
|
| 2014 |
Hakimi AA, Jacobsen A, Mano R, Gonen M, Voss MH, Reuter VE, Rathmell K, Maranchie JK, Appleman LJ, Tamboli P, Signoretti S, Choueiri TK, Russo P, Motzer RJ, Hsieh J. Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis. Journal of Clinical Oncology. 32: 432-432. DOI: 10.1200/Jco.2014.32.4_Suppl.432 |
0.371 |
|
| 2014 |
Ho TH, Choueiri TK, D'Amelio A, Hsieh J, De Souza PL, Deen KC, Langmuir PB, Liu Y, Motzer RJ. The effect of SETD2 mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ. Journal of Clinical Oncology. 32: 4583-4583. DOI: 10.1200/Jco.2014.32.15_Suppl.4583 |
0.418 |
|
| 2014 |
Voss MH, Chen D, Marker M, Hamilton M, Kalfoglou C, Hsieh J, Knox JJ, Anak O, Motzer RJ. Identification and validation of predictive biomarkers (BM) for everolimus (EVE) in metastatic renal cell carcinoma: Analysis of 442 patients on RECORD-3. Journal of Clinical Oncology. 32: 4531-4531. DOI: 10.1200/Jco.2014.32.15_Suppl.4531 |
0.333 |
|
| 2014 |
Hakimi AA, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB, Mano R, Russo P, Ogawa S, Hsieh J, Reuter V, Tickoo S. Mp23-16 Tceb1-Mutated Renal Cell Carcinoma: A Distinct Genomic And Morphologic Subtype The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.884 |
0.479 |
|
| 2014 |
Hakimi AA, Chevinsky M, Hsieh JJ, Sander C, Sinha R. Mp23-11 Genomic Comparison Of Renal Cell Carcinoma Cell Lines To Human Tumors The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.879 |
0.476 |
|
| 2014 |
Hakimi AA, Jacobsen A, Mano R, Gonen M, Voss MH, Reuter VE, Rathmell WK, Maranchie JK, Appleman LJ, Tamboli P, Signoretti S, Choueiri TK, Russo P, Motzer RJ, Hsieh JJ. MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.877 |
0.463 |
|
| 2014 |
Sankin A, Mikkilineni N, Hakimi AA, Silk M, Liang Y, Mano R, Durack JC, Coleman J, Russo P, Hsieh J. MP23-07 REGIONAL GENETIC VARIABILITY DETECTED WITH RENAL TUMOR BIOPSIES: IMPLICATIONS IN BIOMARKER DEVELOPMENT Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.875 |
0.369 |
|
| 2014 |
Hakimi AA, Ostrovnaya I, Jacobsen A, Coleman J, Russo P, Mano R, Sankin A, Motzer RJ, Purdue M, Pomerantz M, Freedman M, Choueiri T, Hsieh JJ, Klein RJ. Mp36-02 Validation And Genomic Interrogation Of The Met Variant Rs11762213 As A Predictor Of Adverse Outcomes In Clear Cell Renal Cell Carcinoma The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1066 |
0.441 |
|
| 2014 |
Hakimi AA, Tickoo SK, Xu J, Lee C, Mano R, Chen Y, Stirdivant S, Neri B, Wolfert R, Fine SW, Al-Ahmadie H, Gopalan A, Russo P, Reuter VE, Hsieh JJ. MP35-19 SORBITOL AS A NOVEL MECHANISM OF HYPOXIA-INDUCIBLE FACTOR (HIF) PATHWAY ACTIVATION IN CLEAR CELL PAPILLARY RENAL CELL CARCINOMA (CCPRCC) Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1062 |
0.462 |
|
| 2013 |
Jacobsen A, Mikkilineni N, Fiegoli B, Blass S, Grigoryev Y, Viale A, Socci ND, Voss MH, Motzer RJ, Reuter VE, Coleman JA, Russo P, Hsieh J. MicroRNA as novel blood-based biomarkers in clear cell renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 375. PMID 28136910 DOI: 10.1200/Jco.2013.31.6_Suppl.375 |
0.409 |
|
| 2013 |
Lee CH, Cross JR, Li Z, Chen Y, Neri B, Reuter VE, Motzer RJ, Russo P, Hsieh J. Global metabolic profiling of clear cell renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 379. PMID 28136900 DOI: 10.1200/Jco.2013.31.6_Suppl.379 |
0.488 |
|
| 2013 |
Ostrovnaya I, Voss MH, Motzer RJ, Russo P, Reuter VE, Hsieh J. Association of mutations in chromatin modifiers with poor survival in clear cell renal cell carcinoma: Analysis of the Cancer Genome Atlas Project. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 360. PMID 28136797 DOI: 10.1200/Jco.2013.31.6_Suppl.360 |
0.496 |
|
| 2013 |
Bastos DA, Karlo C, Patil S, Ajeti A, Hakimi AA, Feldman DR, Molina AM, Berger MF, Hsieh J, Motzer RJ. Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: Association of long-term responses and oncogenomic events. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 391. PMID 28136739 DOI: 10.1200/Jco.2013.31.6_Suppl.391 |
0.474 |
|
| 2013 |
Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R, Cowley GS, Lizotte P, Liberzon E, Bair S, Root DE, Tamayo P, Tsherniak A, Cheng SC, Tabak B, ... ... Hsieh JJ, et al. SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell. 24: 738-50. PMID 24332042 DOI: 10.1016/J.Ccr.2013.10.025 |
0.351 |
|
| 2013 |
Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, Mikklineni N, Fiegoli B, Kim PH, Voss MH, Shen H, Laird PW, Sander C, Reuter VE, Motzer RJ, ... Hsieh JJ, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. Journal of the National Cancer Institute. 105: 1862-70. PMID 24285872 DOI: 10.1093/Jnci/Djt310 |
0.381 |
|
| 2013 |
Oyama T, Sasagawa S, Takeda S, Hess RA, Lieberman PM, Cheng EH, Hsieh JJ. Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs. Developmental Cell. 27: 188-200. PMID 24176642 DOI: 10.1016/J.Devcel.2013.09.025 |
0.536 |
|
| 2013 |
Takeda S, Liu H, Sasagawa S, Dong Y, Trainor PA, Cheng EH, Hsieh JJ. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. The Journal of Clinical Investigation. 123: 3154-65. PMID 23934123 DOI: 10.1172/Jci65566 |
0.578 |
|
| 2013 |
Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nature Genetics. 45: 849-50. PMID 23892664 DOI: 10.1038/Ng.2708 |
0.48 |
|
| 2013 |
Voss MH, Hsieh JJ, Motzer RJ. Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma. Cancer Journal (Sudbury, Mass.). 19: 299-306. PMID 23867510 DOI: 10.1097/Ppo.0B013E31829D5Cff |
0.412 |
|
| 2013 |
Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ. Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clinical Genitourinary Cancer. 11: 297-302. PMID 23707221 DOI: 10.1016/J.Clgc.2013.04.001 |
0.394 |
|
| 2013 |
Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, ... Hsieh JJ, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3259-67. PMID 23620406 DOI: 10.1158/1078-0432.Ccr-12-3886 |
0.59 |
|
| 2013 |
Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Science Signaling. 6: ra20. PMID 23532334 DOI: 10.1126/Scisignal.2003483 |
0.509 |
|
| 2013 |
Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nature Medicine. 19: 50-6. PMID 23223005 DOI: 10.1038/Nm.3029 |
0.388 |
|
| 2013 |
Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, ... Hsieh JJ, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. European Urology. 63: 848-54. PMID 23036577 DOI: 10.1016/J.Eururo.2012.09.005 |
0.616 |
|
| 2013 |
Voss MH, Hakimi AA, Chen Y, Pham CG, Brannon AR, Scott SN, Takeda S, Liu H, Motzer RJ, Berger MF, Hsieh J. Effective monotherapy despite intratumor heterogeneity: Clonal convergence within the PI3K pathway and sensitivity to mTOR inhibitors in patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 31: 4573-4573. DOI: 10.1200/Jco.2013.31.15_Suppl.4573 |
0.601 |
|
| 2013 |
Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen Y, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, ... ... Hsieh JJ, et al. Abstract 3515: Pathway convergent evolution underscores treatment response to MTOR inhibitors in kidney cancers. Cancer Research. 73: 3515-3515. DOI: 10.1158/1538-7445.Am2013-3515 |
0.599 |
|
| 2013 |
Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Robertson G, Chu A, Beroukhim R, Cibulskis K, Signoretti S, Vandin F, Wu HT, Raphael BJ, Verhaak RGW, Tamboli P, ... ... Hsieh JJ, et al. Comprehensivemolecular characterization of clear cell renal cell carcinoma Nature. 499: 43-49. DOI: 10.1038/Nature12222 |
0.479 |
|
| 2013 |
Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen Y, Gonen M, Liu H, Takeda S, Tickoo SK, Voss MH, Cheng EH, Reuter VE, Motzer RJ, Russo P, Hsieh JJ. 1068 ADVERSE OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA WITH MUTATIONS OF EPIGENETIC REGULATORS BAP1 AND SETD2 Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.657 |
0.649 |
|
| 2013 |
Hakimi AA, Lee C, Cross JR, Li Z, Chen Y, Neri B, Reuter VE, Motzer R, Russo P, Hsieh JJ. 469 GLOBAL METABOLIC PROFILING OF CLEAR CELL RENAL CELL CARCINOMA Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1860 |
0.456 |
|
| 2013 |
Hakimi AA, Jacobsen A, Mikkilineni N, Fiegoli B, Blass S, Grigoryev Y, Viale A, Socci N, Voss MH, Motzer R, Reuter VE, Coleman J, Russo P, Hsieh JJ. 611 MICRORNA AS NOVEL BLOOD-BASED BIOMARKERS IN CLEAR CELL RENAL CELL CARCINOMA Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.162 |
0.455 |
|
| 2013 |
Hakimi AA, Reuter VE, Russo P, Hsieh JJ. Reply from authors re: James W.F. Catto, Shahrokh F. Shariat. the changing face of renal cell carcinoma: The impact of systematic genetic sequencing on our understanding of this tumor's biology. Eur Urol 2013;63:855-7: Genetic stratification of clear cell renal carcinomas presenting as small renal masses European Urology. 63: 857-858. DOI: 10.1016/J.Eururo.2012.09.055 |
0.44 |
|
| 2012 |
Chen DY, Takeda S, Oyama T, Hsieh JJ. "Targeting Taspase1 for Cancer Therapy"-Response. Cancer Research. 72: 2913. PMID 24619300 DOI: 10.1158/0008-5472.Can-12-1074 |
0.56 |
|
| 2012 |
Chen DY, Lee Y, Van Tine BA, Searleman AC, Westergard TD, Liu H, Tu HC, Takeda S, Dong Y, Piwnica-Worms DR, Oh KJ, Korsmeyer SJ, Hermone A, Gussio R, Shoemaker RH, ... ... Hsieh JJ, et al. A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Research. 72: 736-46. PMID 22166309 DOI: 10.1158/0008-5472.Can-11-2584 |
0.524 |
|
| 2012 |
Voss MH, Hakimi AA, Scott SN, Takeda S, Liu H, Chen Y, Motzer RJ, Berger MF, Hsieh J. Genetic determinants of long-term response to rapalog therapy in advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 30: 4604-4604. DOI: 10.1200/Jco.2012.30.15_Suppl.4604 |
0.591 |
|
| 2010 |
Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, Pandita TK, Cheng EH, Hsieh JJ. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature. 467: 343-6. PMID 20818375 DOI: 10.1038/Nature09350 |
0.484 |
|
| 2010 |
Hou MM, Hsieh JJ, Chang NJ, Huang HY, Wang HM, Chuang CK, Hsu T, Chang JW. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Clinical Drug Investigation. 30: 799-804. PMID 20635828 DOI: 10.2165/11537220-000000000-00000 |
0.339 |
|
| 2010 |
Chen DY, Liu H, Takeda S, Tu HC, Sasagawa S, Van Tine BA, Lu D, Cheng EH, Hsieh JJ. Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. Cancer Research. 70: 5358-67. PMID 20516119 DOI: 10.1158/0008-5472.Can-10-0027 |
0.547 |
|
| 2010 |
Hou MM, Chang JW, Pang ST, Chiang YJ, Shen YC, Liao SK, Hsieh JJ, Yeh KY, Chang NJ, Chuang CK. Characterization of the response of dendritic cells and regulatory T cells to tumor antigens in patients with renal cell carcinoma. Chang Gung Medical Journal. 33: 25-35. PMID 20184792 |
0.343 |
|
| 2008 |
Liu H, Takeda S, Cheng EH, Hsieh JJ. Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia. Cell Cycle (Georgetown, Tex.). 7: 428-35. PMID 18235233 DOI: 10.4161/Cc.7.4.5426 |
0.509 |
|
| 2006 |
Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH, Hsieh JJ. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes & Development. 20: 2397-409. PMID 16951254 DOI: 10.1101/Gad.1449406 |
0.536 |
|
| 2006 |
Hsieh JJ, Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH. Proteolysis of MLL Family Proteins Is Essential for Taspase1−Orchestrated Cell Cycle Progression. Blood. 108: 769-769. DOI: 10.1182/Blood.V108.11.769.769 |
0.576 |
|
| 2002 |
Armstrong SA, Hsieh JJ, Korsmeyer SJ. Genomic approaches to the pathogenesis and treatment of acute lymphoblastic leukemias. Current Opinion in Hematology. 9: 339-44. PMID 12042709 DOI: 10.1097/00062752-200207000-00012 |
0.317 |
|
| Show low-probability matches. |